Skip to main content
. 2023 Oct 20;7(23):7243–7253. doi: 10.1182/bloodadvances.2023011384

Table 1.

Baseline characteristics

Characteristic All patients, N (%)
Median age (y) 63
IPI score
 <3 65 (55)
 ≥3 49 (42)
 Unknown 3 (3)
Classification
 DLBCL 95 (81)
 HGBL 22 (19)
Prior indolent lymphoma
 No 100 (85)
 Yes 17 (15)
Cell of origin
 Nongerminal center 58 (50)
 Germinal center 58 (50)
 Indeterminate 1 (0)
MYC rearrangement (n = 111)
 No 88 (75)
 Yes 23 (20)
Double-hit lymphoma (n = 112)
 No 101 (86)
 Yes 11 (9)
TP53 mutation
 No 75 (64)
 Yes 42 (36)
SOCS1 mutation
 No 88 (75)
 Yes 29 (25)
B2M mutation
 No 93 (79)
 Yes 24 (21)
CREBBP mutation
 No 94 (80)
 Yes 23 (20)
TNFRSF14 mutation
 No 97 (83)
 Yes 20 (17)
TBL1XR1 mutation (n = 62)
 No 52 (84)
 Yes 10 (16)
GNA13 mutation
 No 100 (85)
 Yes 17 (15)
MYC mutation (n = 62)
 No 54 (87)
 Yes 8 (13)
CIITA mutation
 No 103 (88)
 Yes 14 (12)
DICER1 mutation (n = 62)
 No 55 (89)
 Yes 7 (11)
BCL2 mutation (n = 62)
 No 55 (89)
 Yes 7 (11)
EZH2 mutation
 No 104 (89)
 Yes 13 (11)
ATM mutation
 No 104 (89)
 Yes 13 (11)
TNFAIP3 mutation
 No 105 (90)
 Yes 12 (10)
CARD11 mutation
 No 105 (90)
 Yes 12 (10)
Genetic subtype based on LymphGen
 Other 82 (70)
 EZB 26 (22)
 MCD 5 (4)
 ST2 5 (4)